Artículo
Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Autor/es | Bramlage, Peter
Swift, Stephanie L. Thoenes, Martin Minguet, Joan Ferrero Rodríguez, Carmen |
Departamento | Universidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéutica |
Fecha de publicación | 2016-01 |
Fecha de depósito | 2023-12-22 |
Publicado en |
|
Resumen | Pharmaceutical antagonism of the mineralocorticoid receptor (MR) can protect against organ damage caused by elevated aldosterone levels in patients experiencing heart failure (HF), chronic kidney disease (CKD), primary ... Pharmaceutical antagonism of the mineralocorticoid receptor (MR) can protect against organ damage caused by elevated aldosterone levels in patients experiencing heart failure (HF), chronic kidney disease (CKD), primary aldosteronism, and hypertension. While traditional steroid-based MR antagonists effectively reduce mortality rates and extend patient survival, their broad application has been limited by significant side effects, most notably hyperkalaemia. Recently, finerenone (BAY 94-8862) has emerged as a next-generation non-steroidal dihydropyridine-based MR antagonist designed to minimize off-target effects while maintaining potent efficacy. In this review, the outcomes of finerenone therapy in several diseases associated with MR activity are explored. The (pre-) clinical efficacy of finerenone is compared with that of traditional steroid-based MR antagonists. Finally, recent and ongoing clinical trials using finerenone to treat chronic HF, CKD, and diabetic nephropathy are discussed. Taken together, pre-clinical and clinical evidence suggests that finerenone may achieve equivalent organ-protective effects with reduced levels of electrolyte disturbance compared with traditional steroid-based MR antagonists. This supports further clinical development of finerenone for the treatment of cardiovascular and renal disease. |
Cita | Bramlage, P., Swift, S.L., Thoenes, M., Minguet, J. y Ferrero Rodríguez, C. (2016). Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. European Journal of Heart Failure, 18 (1), 28-37. https://doi.org/10.1002/ejhf.444. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
10.1002ejhf.444.pdf | 426.3Kb | [PDF] | Ver/ | Versión aceptada |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.